Huilan J Cheng, MD
Gastroenterology · Alamo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 32 years
- Graduated 1994
Offices
3 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: Alameda Hospital · Alta Bates Summit Medical Center - Alta Bates Camp · John Muir Medical Center - Walnut Creek Campus · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cheng’s office at (925) 932-6330 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A93605 · Current
Licensed to practise in California · since 2005 · expires 2027-03-31 · Peking Medical University Aka Beijing Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- East Bay Endoscopy CenterAmbulatory Surgery Center · Emeryville, CAOwner · accredited by JCInitial AccreditationNo inspections published
- East Bay Endoscopy Center, LP dba East BayEndoscopy CenterAmbulatory Surgery Center · Emeryville, CA7% owner since 2011 · accredited by AAAHCAccreditation Renewed2 inspections, 1 with deficiencies · last 2024-05-02: Requirements Met
- Walnut Creek Endoscopy CenterAmbulatory Surgery Center · Walnut Creek, CAOwner · accredited by JCAccreditation Renewed2 inspections, 2 with deficiencies · last 2017-09-06: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alameda HospitalAlameda, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Alameda Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 4 the same, 0 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0 to 2.12) · 119 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.45 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.3 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.7 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 532 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,887 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,916 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.37 (0.77 to 5.96) · 80 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (0.58 to 4.02) · 85 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 1.23) · 1,359 cases | No different | Jul 2022 – Jun 2024 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 98 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.4 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -3.6 · 242 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 244 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 40 cases | None | Jul 2023 – Jun 2025 |
What patients said (319 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$154,854
Medicare paid this office $154,854 for 615 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 163 | $34,789 | $211 |
| Return visit (30+ min) | 246 | $34,111 | $108 |
| New patient visit (45+ min) | 216 | $31,061 | $144 |
| Biopsy of large bowel using a flexible endoscope | 228 | $18,992 | $82 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 158 | $13,289 | $81 |
See all 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 163 | $34,789 | $211 |
| Return visit (30+ min) | 246 | $34,111 | $108 |
| New patient visit (45+ min) | 216 | $31,061 | $144 |
| Biopsy of large bowel using a flexible endoscope | 228 | $18,992 | $82 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 158 | $13,289 | $81 |
| Short return visit (20+ min) | 44 | $3,758 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,727 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,403 | $141 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,669 | $152 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 20 | $1,498 | $71 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,050 | $87 |
| New patient visit (30+ min) | 12 | $1,012 | $84 |
Procedures Medicare counted
| Colonoscopy | 342 | More than 98% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 190 | More than 89% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of large bowel using a flexible endoscope | 158 | 125 | 163 | 201 | 185 | 232 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 115 | 108 | 144 | 158 | 137 | 164 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 76 | 69 | 96 | 113 | 98 | 165 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | 14 | 16 | 11 | – | 12 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | 11 | – | – | – | 11 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
615 Original Medicare patients in 2024. Average age 74 · Under 65 4% · 85 and older 7% · Women 74% · Also on Medicaid 14% · Health risk score 0.95. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 58% · Diabetes 21% · Chronic kidney disease 19% · Depression 18% · Cancer 17% · Atrial fibrillation 14% · Coronary heart disease 12% · Heart failure 8% · COPD 8% · Stroke 4% · Dementia 3%.
The office billed $1,023,702, Medicare allowed $210,945 and paid $154,854; for 1,339 services of 35 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 615 | 1,339 | 74 | 0.95 | $1,023,702 | $154,854 |
| 2023 | 538 | 1,153 | 74 | 0.96 | $631,027 | $136,684 |
| 2022 | 532 | 1,306 | 74 | 1.00 | $808,752 | $146,541 |
| 2021 | 507 | 1,276 | 74 | 1.10 | $753,607 | $146,300 |
| 2020 | 427 | 974 | 73 | 1.10 | $454,493 | $102,234 |
| 2019 | 450 | 1,042 | 73 | 1.14 | $549,497 | $117,437 |
| 2018 | 422 | 932 | 73 | 1.24 | $494,273 | $109,398 |
| 2017 | 436 | 999 | 73 | 1.21 | $552,709 | $110,190 |
| 2016 | 426 | 2,410 | 73 | 1.21 | $555,594 | $121,175 |
| 2015 | 431 | 9,165 | 72 | 1.39 | $566,661 | $162,371 |
| 2014 | 442 | 1,835 | 73 | 1.31 | $491,753 | $115,753 |
| 2013 | 521 | 1,219 | 73 | 1.49 | $602,842 | $143,471 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 213 | $30,398 | $107 |
| New patient visit (45+ min) | 189 | $26,034 | $138 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 98 | $22,160 | $226 |
| Biopsy of large bowel using a flexible endoscope | 184 | $20,404 | $110 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 128 | $11,377 | $83 |
| Short return visit (20+ min) | 58 | $5,105 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,289 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,929 | $71 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 13 | $2,428 | $173 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 15 | $2,016 | $92 |
2022: 16 services
| Return visit (30+ min) | 188 | $27,727 | $110 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 113 | $23,395 | $207 |
| New patient visit (45+ min) | 162 | $22,645 | $140 |
| Biopsy of large bowel using a flexible endoscope | 200 | $21,206 | $106 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 151 | $12,237 | $77 |
| Telephone medical discussion with physician, 21-30 minutes | 63 | $7,302 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,851 | $173 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 22 | $4,467 | $203 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,082 | $63 |
| Extended patient service without direct patient contact, first hour | 37 | $3,297 | $89 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | $2,225 | $72 |
| Short return visit (20+ min) | 29 | $2,150 | $74 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 14 | $1,564 | $98 |
| Telephone medical discussion with physician, 5-10 minutes | 23 | $1,352 | $44 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,005 | $91 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 21 | $348 | $13 |
2021: 16 services
| Return visit (30+ min) | 181 | $30,226 | $121 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 96 | $21,340 | $222 |
| New patient visit (45+ min) | 131 | $19,730 | $151 |
| Telephone medical discussion with physician, 21-30 minutes | 108 | $16,166 | $115 |
| Biopsy of large bowel using a flexible endoscope | 163 | $15,477 | $95 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 142 | $11,719 | $81 |
| Telephone medical discussion with physician, 11-20 minutes | 34 | $4,063 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,813 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,932 | $64 |
| Short return visit (20+ min) | 30 | $2,640 | $82 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 11 | $2,336 | $212 |
| Extended patient service without direct patient contact, first hour | 17 | $1,730 | $102 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,529 | $96 |
| Telephone medical discussion with physician, 5-10 minutes | 27 | $1,501 | $44 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 15 | $456 | $27 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 23 | $290 | $11 |
2020: 15 services
| Return visit (30+ min) | 140 | $17,612 | $97 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 69 | $14,494 | $210 |
| Biopsy of large bowel using a flexible endoscope | 125 | $14,014 | $112 |
| New patient visit (45+ min) | 86 | $13,498 | $157 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 105 | $8,883 | $82 |
| Short return visit (20+ min) | 74 | $5,654 | $67 |
| Short return visit | 63 | $3,659 | $45 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,329 | $185 |
| Long return visit (40+ min) | 20 | $2,925 | $139 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 14 | $2,893 | $207 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,724 | $66 |
| New patient visit (30+ min) | 30 | $2,568 | $86 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,735 | $158 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,210 | $86 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $684 | $53 |
2019: 13 services
| Biopsy of large bowel using a flexible endoscope | 155 | $17,069 | $108 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 75 | $16,690 | $220 |
| Return visit (30+ min) | 141 | $16,260 | $92 |
| New patient visit (45+ min) | 108 | $14,059 | $130 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 110 | $9,964 | $87 |
| Short return visit (20+ min) | 102 | $7,348 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,025 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,436 | $63 |
| New patient visit (30+ min) | 41 | $3,705 | $90 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 16 | $3,388 | $212 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $2,096 | $161 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,657 | $97 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 13 | $1,022 | $79 |
2018: 14 services
| Return visit (30+ min) | 148 | $18,034 | $92 |
| New patient visit (45+ min) | 129 | $16,798 | $130 |
| Biopsy of large bowel using a flexible endoscope | 123 | $14,212 | $116 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 56 | $12,694 | $227 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 100 | $9,180 | $88 |
| Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 12-25 targets | 15 | $7,564 | $504 |
| Short return visit (20+ min) | 77 | $5,597 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,036 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,777 | $174 |
| New patient visit (30+ min) | 31 | $2,374 | $77 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,316 | $211 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 11 | $2,315 | $210 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 17 | $1,302 | $65 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,185 | $108 |
2017: 14 services
| New patient visit (45+ min) | 152 | $19,031 | $125 |
| Biopsy of large bowel using a flexible endoscope | 154 | $18,449 | $118 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 66 | $14,932 | $226 |
| Return visit (30+ min) | 135 | $14,511 | $85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 124 | $10,938 | $85 |
| Short return visit (20+ min) | 78 | $5,572 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $3,771 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,947 | $173 |
| New patient visit (30+ min) | 34 | $2,793 | $82 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 13 | $2,231 | $172 |
| New patient visit (60+ min) | 12 | $2,221 | $185 |
| Long return visit (40+ min) | 12 | $1,578 | $121 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,515 | $95 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 12 | $1,059 | $71 |
2016: 16 services
| Biopsy of large bowel using a flexible endoscope | 127 | $17,351 | $137 |
| New patient visit (45+ min) | 115 | $14,607 | $127 |
| Return visit (30+ min) | 126 | $13,248 | $89 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 52 | $11,946 | $230 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 105 | $8,662 | $82 |
| Pathology examination of tissue using a microscope, intermediate complexity | 77 | $7,849 | $33 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $7,660 | $170 |
| Short return visit (20+ min) | 80 | $6,099 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $5,146 | $62 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 19 | $3,667 | $193 |
| Diagnostic exam of large bowel using a flexible endoscope | 15 | $2,517 | $168 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,412 | $201 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,102 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,965 | $89 |
| New patient visit (30+ min) | 23 | $1,786 | $78 |
| Long return visit (40+ min) | 13 | $1,753 | $125 |
2015: 14 services
| Biopsy of large bowel using a flexible endoscope | 101 | $17,476 | $171 |
| New patient visit (45+ min) | 102 | $13,706 | $134 |
| Return visit (30+ min) | 119 | $12,355 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $11,782 | $171 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 39 | $10,336 | $258 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $9,373 | $62 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 91 | $8,576 | $92 |
| Short return visit (20+ min) | 81 | $6,256 | $65 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 18 | $3,875 | $215 |
| Long return visit (40+ min) | 25 | $3,347 | $129 |
| Diagnostic exam of large bowel using a flexible endoscope | 15 | $2,788 | $186 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,600 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,975 | $90 |
| New patient visit (30+ min) | 23 | $1,672 | $73 |
2014: 13 services
| New patient visit (45+ min) | 138 | $18,350 | $133 |
| Biopsy of large bowel using a flexible endoscope | 104 | $17,127 | $160 |
| Short return visit (20+ min) | 159 | $13,398 | $58 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $9,803 | $251 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 103 | $9,461 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $8,181 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,250 | $165 |
| Return visit (30+ min) | 48 | $4,825 | $86 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 17 | $3,790 | $223 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $3,431 | $172 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,905 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,607 | $89 |
| New patient visit (30+ min) | 21 | $1,535 | $73 |
2013: 13 services
| Biopsy of large bowel using a flexible endoscope | 143 | $24,516 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $17,723 | $166 |
| New patient visit (45+ min) | 130 | $17,215 | $132 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 129 | $14,309 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 97 | $12,462 | $60 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 45 | $12,291 | $262 |
| Short return visit (20+ min) | 141 | $12,116 | $60 |
| Return visit (30+ min) | 54 | $4,329 | $76 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 17 | $3,978 | $234 |
| Diagnostic exam of large bowel using a flexible endoscope | 21 | $3,743 | $178 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $3,731 | $233 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $3,414 | $114 |
| New patient visit (30+ min) | 35 | $2,748 | $79 |
Medicaid work
$1,085 in 2019
Medicaid paid $1,085 for 30 billed services this clinician did in 2019, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 30 | $1,085 |
| 2019 | 30 | 1 | 12 | $1,085 |
Drugs they prescribed that Part D paid
$778,377
Pharmacies billed $778,377 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,616) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
1,167 generic and 449 brand-name prescriptions · $778,377 in drug cost · 75 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Creon | 94 | $107,169 | $1,140 |
| Zenpep | 63 | $90,548 | $1,437 |
| Vemlidy | 28 | $61,507 | $2,197 |
| Linzess | 60 | $49,732 | $829 |
| Xifaxan | 14 | $32,977 | $2,355 |
See all 24 drugs
| Creon | 94 | $107,169 | $1,140 |
| Zenpep | 63 | $90,548 | $1,437 |
| Vemlidy | 28 | $61,507 | $2,197 |
| Linzess | 60 | $49,732 | $829 |
| Xifaxan | 14 | $32,977 | $2,355 |
| Entecavir | 25 | $28,220 | $1,129 |
| Sod Sulf-Potass Sulf-Mag Sulf | 243 | $15,938 | $66 |
| Viread | 11 | $13,789 | $1,254 |
| Mesalamine | 17 | $12,727 | $749 |
| Motegrity | 12 | $8,273 | $689 |
| Dexilant | 14 | $5,476 | $391 |
| Ursodiol | 23 | $4,318 | $188 |
| Pantoprazole | 299 | $4,175 | $14 |
| Tenofovir Disoproxil | 11 | $3,896 | $354 |
| Omeprazole | 250 | $3,269 | $13 |
| Peg 3350-Electrolyte | 87 | $1,851 | $21 |
| Tetracycline | 11 | $1,681 | $153 |
| Famotidine | 90 | $1,012 | $11 |
| Esomeprazole Magnesium | 19 | $819 | $43 |
| Lubiprostone | 12 | $628 | $52 |
| Dicyclomine | 17 | $588 | $35 |
| Rabeprazole | 12 | $381 | $32 |
| Lansoprazole | 14 | $328 | $23 |
| Metronidazole | 29 | $259 | $9 |
Year by year
| 2024 | 1,616 | 622 | 0% (0) | 28% | $778,377 |
| 2023 | 1,456 | 571 | 0% (0) | None | $639,725 |
| 2022 | 1,273 | 487 | 0% (0) | 37% | $449,127 |
| 2021 | 1,175 | 499 | 0% (0) | None | $385,088 |
| 2020 | 893 | 349 | 0% (0) | None | $203,698 |
| 2019 | 979 | 403 | 0% (0) | None | $217,597 |
| 2018 | 924 | 250 | 0% (0) | 27% | $440,639 |
| 2017 | 1,201 | 333 | 0% (0) | 39% | $824,599 |
| 2016 | 1,380 | 424 | 0% (0) | 46% | $746,956 |
| 2015 | 1,183 | 382 | None | 47% | $1,118,569 |
| 2014 | 1,177 | 390 | None | None | $361,083 |
| 2013 | 1,075 | 378 | None | None | $186,673 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Humira(Cf) | 14 | $104,670 | $7,476 |
| Zenpep | 73 | $95,547 | $1,309 |
| Creon | 53 | $57,184 | $1,079 |
| Linzess | 67 | $52,482 | $783 |
| Vemlidy | 21 | $40,292 | $1,919 |
| Xifaxan | 17 | $39,087 | $2,299 |
| Mesalamine | 34 | $27,141 | $798 |
| Viread | 13 | $19,562 | $1,505 |
| Sod Sulf-Potass Sulf-Mag Sulf | 229 | $18,029 | $79 |
| Entecavir | 14 | $11,257 | $804 |
| Ursodiol | 25 | $6,778 | $271 |
| Dexlansoprazole Dr | 11 | $5,440 | $495 |
| Tenofovir Disoproxil | 11 | $5,317 | $483 |
| Pantoprazole | 282 | $5,228 | $19 |
| Balsalazide Disodium | 11 | $3,391 | $308 |
| Omeprazole | 222 | $3,035 | $14 |
| Peg 3350-Electrolyte | 72 | $1,885 | $26 |
| Esomeprazole Magnesium | 19 | $1,364 | $72 |
| Famotidine | 86 | $1,130 | $13 |
| Rabeprazole | 11 | $1,066 | $97 |
| Dicyclomine | 13 | $838 | $64 |
| Metronidazole | 21 | $235 | $11 |
2022: 18 drugs
| Creon | 52 | $64,526 | $1,241 |
| Zenpep | 49 | $63,103 | $1,288 |
| Linzess | 52 | $32,948 | $634 |
| Entecavir | 20 | $25,348 | $1,267 |
| Xifaxan | 11 | $25,107 | $2,282 |
| Vemlidy | 11 | $24,106 | $2,191 |
| Mesalamine | 18 | $17,392 | $966 |
| Suprep | 146 | $16,758 | $115 |
| Viread | 11 | $14,754 | $1,341 |
| Ursodiol | 18 | $7,298 | $405 |
| Colesevelam | 11 | $5,864 | $533 |
| Pantoprazole | 265 | $5,691 | $21 |
| Sod Sulf-Potass Sulf-Mag Sulf | 57 | $4,622 | $81 |
| Omeprazole | 234 | $2,961 | $13 |
| Sutab | 15 | $2,475 | $165 |
| Peg 3350-Electrolyte | 60 | $1,107 | $18 |
| Famotidine | 66 | $971 | $15 |
| Esomeprazole Magnesium | 13 | $863 | $66 |
2021: 18 drugs
| Creon | 56 | $69,764 | $1,246 |
| Suprep | 276 | $30,656 | $111 |
| Zenpep | 32 | $27,743 | $867 |
| Linzess | 23 | $21,248 | $924 |
| Entecavir | 17 | $20,526 | $1,207 |
| Mesalamine | 17 | $16,837 | $990 |
| Viread | 12 | $16,095 | $1,341 |
| Dexilant | 14 | $10,205 | $729 |
| Ursodiol | 19 | $9,567 | $504 |
| Mesalamine Er | 11 | $7,284 | $662 |
| Pantoprazole | 230 | $4,975 | $22 |
| Omeprazole | 201 | $3,308 | $16 |
| Budesonide Ec | 11 | $2,497 | $227 |
| Rabeprazole | 13 | $1,584 | $122 |
| Esomeprazole Magnesium | 12 | $1,096 | $91 |
| Ondansetron Odt | 14 | $1,051 | $75 |
| Famotidine | 44 | $621 | $14 |
| Peg 3350-Electrolyte | 23 | $321 | $14 |
2020: 16 drugs
| Creon | 26 | $30,910 | $1,189 |
| Xifaxan | 14 | $27,558 | $1,968 |
| Mesalamine | 23 | $18,891 | $821 |
| Viread | 13 | $17,436 | $1,341 |
| Linzess | 17 | $15,603 | $918 |
| Suprep | 144 | $15,193 | $106 |
| Dexilant | 18 | $13,003 | $722 |
| Ursodiol | 13 | $5,675 | $437 |
| Pantoprazole | 185 | $3,718 | $20 |
| Omeprazole | 181 | $3,157 | $17 |
| Balsalazide Disodium | 11 | $2,503 | $228 |
| Ondansetron Odt | 16 | $670 | $42 |
| Famotidine | 46 | $569 | $12 |
| Peg 3350-Electrolyte | 16 | $250 | $16 |
| Dicyclomine | 12 | $230 | $19 |
| Methotrexate | 12 | $191 | $16 |
2019: 18 drugs
| Mesalamine | 29 | $21,665 | $747 |
| Suprep | 194 | $19,401 | $100 |
| Xifaxan | 11 | $18,295 | $1,663 |
| Viread | 14 | $17,737 | $1,267 |
| Creon | 15 | $16,277 | $1,085 |
| Linzess | 15 | $13,815 | $921 |
| Zenpep | 11 | $13,597 | $1,236 |
| Dexilant | 25 | $13,207 | $528 |
| Amitiza | 16 | $8,589 | $537 |
| Esomeprazole Magnesium | 21 | $4,597 | $219 |
| Entecavir | 14 | $4,161 | $297 |
| Omeprazole | 200 | $3,499 | $17 |
| Pantoprazole | 192 | $2,809 | $15 |
| Balsalazide Disodium | 13 | $2,424 | $186 |
| Peg 3350-Electrolyte | 20 | $307 | $15 |
| Famotidine | 19 | $244 | $13 |
| Gavilyte-N | 15 | $229 | $15 |
| Prednisone | 12 | $81 | $7 |
2018: 17 drugs
| Dexilant | 54 | $27,764 | $514 |
| Mesalamine | 33 | $25,601 | $776 |
| Creon | 23 | $24,429 | $1,062 |
| Linzess | 31 | $18,743 | $605 |
| Entecavir | 16 | $13,780 | $861 |
| Zenpep | 17 | $11,788 | $693 |
| Amitiza | 15 | $9,570 | $638 |
| Tenofovir Disoproxil | 23 | $7,802 | $339 |
| Esomeprazole Magnesium | 26 | $6,515 | $251 |
| Pantoprazole | 238 | $3,942 | $17 |
| Omeprazole | 191 | $3,459 | $18 |
| Suprep | 31 | $2,898 | $93 |
| Mercaptopurine | 11 | $2,191 | $199 |
| Lansoprazole | 13 | $635 | $49 |
| Polyethylene Glycol 3350 | 13 | $546 | $42 |
| Dicyclomine | 17 | $370 | $22 |
| Ranitidine | 13 | $168 | $13 |
2017: 24 drugs
| Viread | 43 | $51,441 | $1,196 |
| Lialda | 34 | $49,136 | $1,445 |
| Xifaxan | 27 | $40,111 | $1,486 |
| Entecavir | 29 | $36,830 | $1,270 |
| Dexilant | 75 | $28,268 | $377 |
| Zenpep | 30 | $26,230 | $874 |
| Linzess | 38 | $21,093 | $555 |
| Mesalamine | 20 | $16,405 | $820 |
| Creon | 13 | $11,660 | $897 |
| Ursodiol | 15 | $10,397 | $693 |
| Suprep | 111 | $9,656 | $87 |
| Amitiza | 15 | $6,598 | $440 |
| Esomeprazole Magnesium | 19 | $6,075 | $320 |
| Pantoprazole | 241 | $3,636 | $15 |
| Omeprazole | 215 | $3,431 | $16 |
| Mercaptopurine | 18 | $3,314 | $184 |
| Ondansetron Odt | 15 | $1,108 | $74 |
| Polyethylene Glycol 3350 | 16 | $1,096 | $69 |
| Dicyclomine | 15 | $500 | $33 |
| Clarithromycin | 11 | $434 | $39 |
| Peg 3350-Electrolyte | 13 | $170 | $13 |
| Lidocaine Hcl Viscous | 13 | $127 | $10 |
| Amoxicillin | 12 | $119 | $10 |
| Ranitidine | 25 | $117 | $5 |
2016: 24 drugs
| Humira | 19 | $84,421 | $4,443 |
| Lialda | 43 | $56,085 | $1,304 |
| Xifaxan | 31 | $53,359 | $1,721 |
| Zenpep | 58 | $42,571 | $734 |
| Viread | 37 | $41,436 | $1,120 |
| Entecavir | 28 | $30,768 | $1,099 |
| Dexilant | 69 | $23,540 | $341 |
| Suprep | 222 | $18,358 | $83 |
| Creon | 22 | $13,551 | $616 |
| Linzess | 33 | $11,973 | $363 |
| Ursodiol | 16 | $8,662 | $541 |
| Esomeprazole Magnesium | 27 | $6,538 | $242 |
| Mesalamine | 11 | $6,422 | $584 |
| Amitiza | 11 | $3,666 | $333 |
| Pantoprazole | 217 | $3,023 | $14 |
| Omeprazole | 239 | $2,827 | $12 |
| Mercaptopurine | 13 | $761 | $59 |
| Dicyclomine | 33 | $563 | $17 |
| Polyethylene Glycol 3350 | 12 | $556 | $46 |
| Peg 3350-Electrolyte | 28 | $479 | $17 |
| Gavilyte-N | 11 | $225 | $20 |
| Metronidazole | 12 | $184 | $15 |
| Amoxicillin | 11 | $97 | $9 |
| Ranitidine | 14 | $89 | $6 |
2015: 27 drugs
| Harvoni | 26 | $820,189 | $31,546 |
| Humira | 17 | $53,706 | $3,159 |
| Xifaxan | 22 | $33,931 | $1,542 |
| Lialda | 25 | $24,580 | $983 |
| Viread | 34 | $24,347 | $716 |
| Dexilant | 81 | $23,056 | $285 |
| Entecavir | 11 | $16,286 | $1,481 |
| Zenpep | 23 | $13,201 | $574 |
| Suprep | 156 | $12,670 | $81 |
| Asacol Hd | 12 | $8,646 | $721 |
| Ursodiol | 13 | $8,184 | $630 |
| Esomeprazole Magnesium | 17 | $6,920 | $407 |
| Linzess | 19 | $5,621 | $296 |
| Amitiza | 11 | $4,004 | $364 |
| Pantoprazole | 222 | $2,645 | $12 |
| Balsalazide Disodium | 11 | $2,491 | $226 |
| Rabeprazole | 11 | $1,999 | $182 |
| Omeprazole | 130 | $1,663 | $13 |
| Mercaptopurine | 14 | $1,079 | $77 |
| Peg 3350-Electrolyte | 47 | $921 | $20 |
| Clarithromycin | 12 | $628 | $52 |
| Lansoprazole | 15 | $618 | $41 |
| Dicyclomine | 34 | $469 | $14 |
| Gavilyte-N | 20 | $408 | $20 |
| Polyethylene Glycol 3350 | 16 | $268 | $17 |
| Spironolactone | 16 | $125 | $8 |
| Amoxicillin | 14 | $107 | $8 |
2014: 19 drugs
| Humira | 20 | $75,831 | $3,792 |
| Lialda | 42 | $37,620 | $896 |
| Dexilant | 83 | $19,775 | $238 |
| Nexium | 40 | $16,605 | $415 |
| Viread | 24 | $14,963 | $623 |
| Suprep | 156 | $12,250 | $79 |
| Ursodiol | 15 | $6,275 | $418 |
| Linzess | 25 | $6,052 | $242 |
| Amitiza | 11 | $4,850 | $441 |
| Omeprazole | 229 | $2,839 | $12 |
| Rabeprazole | 24 | $2,700 | $112 |
| Pantoprazole | 153 | $1,931 | $13 |
| Mercaptopurine | 29 | $1,159 | $40 |
| Welchol | 13 | $972 | $75 |
| Peg-3350 | 42 | $843 | $20 |
| Lansoprazole | 16 | $651 | $41 |
| Gavilyte-N | 32 | $641 | $20 |
| Dicyclomine | 28 | $455 | $16 |
| Polyethylene Glycol 3350 | 18 | $292 | $16 |
2013: 19 drugs
| Lialda | 52 | $37,505 | $721 |
| Baraclude | 17 | $26,584 | $1,564 |
| Nexium | 48 | $17,499 | $365 |
| Viread | 25 | $15,814 | $633 |
| Dexilant | 69 | $14,524 | $210 |
| Aciphex | 15 | $11,406 | $760 |
| Suprep | 154 | $11,136 | $72 |
| Amitiza | 12 | $4,964 | $414 |
| Apriso | 12 | $3,929 | $327 |
| Omeprazole | 208 | $3,809 | $18 |
| Pantoprazole | 167 | $2,767 | $17 |
| Ursodiol | 14 | $2,284 | $163 |
| Lansoprazole | 17 | $1,353 | $80 |
| Mercaptopurine | 19 | $828 | $44 |
| Peg-3350 With Flavor Packs | 39 | $767 | $20 |
| Trilyte With Flavor Packets | 27 | $584 | $22 |
| Gavilyte-N | 13 | $277 | $21 |
| Metoprolol | 11 | $272 | $25 |
| Dicyclomine | 12 | $168 | $14 |
Money from drug and device companies
$2,025 in 2025
| 2025 | 13 | 66 | None | $2,025 |
| 2024 | 15 | 38 | None | $801 |
| 2023 | 14 | 43 | None | $881 |
| 2022 | 12 | 55 | None | $1,004 |
| 2021 | 8 | 47 | None | $783 |
| 2020 | 9 | 36 | None | $676 |
| 2019 | 16 | 61 | None | $1,060 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $489 | 14 payments
|
| Abbvie | Rinvoq | $323 | 13 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $283 | 11 payments
|
| Aimmune Therapeutics | Zenpep | $245 | 6 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $225 | 6 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $152 | 3 payments
|
See all 66 published payments
| Abbvie | Meals · 2025-12-19 | Skyrizi | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-16 | Xifaxan | $23 |
| Abbvie | Meals · 2025-12-15 | Rinvoq | $29 |
| Janssen Biotech | Meals · 2025-12-11 | Tremfya | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-05 | Entyvio | $32 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-17 | Entyvio | $33 |
| Abbvie | Meals · 2025-11-14 | Skyrizi | $29 |
| Abbvie | Meals · 2025-11-07 | Skyrizi | $29 |
| Intercept Pharmaceuticals | Meals · 2025-11-01 | Ocaliva | $27 |
| Pfizer | Meals · 2025-10-31 | Velsipity | $21 |
| Abbvie | Meals · 2025-10-27 | Skyrizi | $28 |
| Exact Sciences | Meals · 2025-10-20 | Cologuard Collection Kit | $32 |
| Janssen Biotech | Meals · 2025-10-03 | Tremfya | $38 |
| Abbvie | Meals · 2025-09-29 | Rinvoq | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-26 | Entyvio | $21 |
| Aimmune Therapeutics | Meals · 2025-09-26 | Zenpep | $32 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-23 | Xifaxan | $104 |
| Abbvie | Meals · 2025-09-19 | Skyrizi | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-15 | Entyvio | $22 |
| Lilly USA | Meals · 2025-09-12 | Omvoh | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-02 | Entyvio | $36 |
| Lilly USA | Meals · 2025-08-28 | Omvoh | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-08-25 | Rezdiffra | $22 |
| Intercept Pharmaceuticals | Meals · 2025-08-22 | Ocaliva | $25 |
| Aimmune Therapeutics | Meals · 2025-08-15 | Zenpep | $33 |
| Janssen Biotech | Meals · 2025-08-12 | Tremfya | $8 |
| Braintree Laboratories | Meals · 2025-08-08 | Sutab | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-01 | Entyvio | $28 |
| Madrigal Pharmaceuticals | Meals · 2025-07-30 | Rezdiffra | $104 |
| Aimmune Therapeutics | Meals · 2025-07-25 | Zenpep | $4 |
| Aimmune Therapeutics | Meals · 2025-07-24 | Zenpep | $23 |
| Abbvie | Meals · 2025-07-14 | Rinvoq | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-07-11 | Rezdiffra | $24 |
| Abbvie | Meals · 2025-06-28 | Rinvoq | $26 |
| Janssen Biotech | Meals · 2025-06-25 | Tremfya | $39 |
| Intercept Pharmaceuticals | Meals · 2025-06-13 | Ocaliva | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-06-07 | Rezdiffra | $20 |
| Lilly USA | Meals · 2025-05-29 | Omvoh | $19 |
| Janssen Biotech | Meals · 2025-05-23 | Tremfya | $33 |
| Madrigal Pharmaceuticals | Meals · 2025-05-23 | Rezdiffra | $24 |
| Abbvie | Meals · 2025-05-16 | Rinvoq | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-09 | Entyvio | $20 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $106 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-30 | Entyvio | $28 |
| Janssen Biotech | Meals · 2025-04-25 | Tremfya | $28 |
| Abbvie | Meals · 2025-04-05 | Rinvoq | $23 |
| Braintree Laboratories | Meals · 2025-03-28 | Sutab | $18 |
| Janssen Biotech | Meals · 2025-03-28 | Tremfya | $12 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-21 | Xifaxan | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-17 | Entyvio | $14 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-14 | Entyvio | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-03-07 | Dupixent | $33 |
| Aimmune Therapeutics | Meals · 2025-03-07 | Zenpep | $29 |
| Lilly USA | Meals · 2025-02-27 | Omvoh | $30 |
| Abbvie | Meals · 2025-02-26 | Linzess | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-14 | Entyvio | $26 |
| Aimmune Therapeutics | Meals · 2025-02-05 | Zenpep | $125 |
| Janssen Biotech | Meals · 2025-01-31 | Tremfya | $36 |
| Madrigal Pharmaceuticals | Meals · 2025-01-31 | Rezdiffra | $31 |
| Janssen Biotech | Meals · 2025-01-29 | Tremfya | $105 |
| Abbvie | Meals · 2025-01-25 | Rinvoq | $20 |
| Janssen Biotech | Meals · 2025-01-24 | Tremfya | $25 |
| Janssen Biotech | Meals · 2025-01-17 | Tremfya | $3 |
| Janssen Biotech | Meals · 2025-01-16 | Tremfya | $16 |
| Phathom Pharmaceuticals | Meals · 2025-01-02 | Voquezna | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $801
| Janssen Biotech | Stelara | $200 | 11 payments
|
| Abbvie | Rinvoq | $174 | 8 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $93 | 4 payments
|
| Celltrion USA | Zymfentra | $57 | 3 payments
|
| Merck Sharp & Dohme | Dificid | $49 | 2 payments
|
| Gilead Sciences | None | $32 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $27 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $23 | 1 payment
|
| Madrigal Pharmaceuticals | Resmetirom | $23 | 1 payment
|
| Lilly USA | Omvoh | $23 | 1 payment
|
| Ipsen Biopharmaceuticals | Iqirvo | $21 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $21 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $20 | 1 payment
|
| Ferring Pharmaceuticals | Rebyota | $19 | 1 payment
|
| Phathom Pharmaceuticals | Voquezna | $18 | 1 payment
|
2023: $881
| AbbVie | Rinvoq | $220 | 10 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $191 | 10 payments
|
| Genzyme | Dupixent | $70 | 3 payments
|
| Janssen Biotech | Stelara | $67 | 3 payments
|
| Gilead Sciences | None | $60 | 3 payments
|
| Ferring Pharmaceuticals | Rebyota | $54 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $49 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $36 | 2 payments
|
| Celgene | Zeposia | $32 | 2 payments
|
| Nestle Healthcare Nutrition | Zenpep | $24 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $23 | 1 payment
|
| Braintree Laboratories | Suflave | $20 | 1 payment
|
| QOL Medical | Sucraid | $18 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $15 | 1 payment
|
2022: $1,004
| Abbvie | Humira | $297 | 16 payments
|
| Janssen Biotech | Stelara | $267 | 15 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $150 | 10 payments
|
| Nestle HealthCare Nutrition | Zenpep | $66 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $57 | 2 payments
|
| Celgene | Zeposia | $31 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $31 | 2 payments
|
| Genzyme | Dupixent | $29 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $19 | 1 payment
|
| Boston Scientific | Emblem Mri S-Icd | $18 | 1 payment
|
| Ferring Pharmaceuticals | None | $18 | 1 payment
|
2021: $783
| Janssen Biotech | Stelara | $268 | 16 payments
|
| AbbVie | Humira | $262 | 18 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $96 | 5 payments
|
| Ferring Pharmaceuticals | Cimzia | $55 | 3 payments
|
| Daiichi Sankyo | Injectafer | $47 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $24 | 1 payment
|
| Celgene | Zeposia | $16 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $15 | 1 payment
|
2020: $676
| Janssen Biotech | Stelara | $190 | 11 payments
|
| AbbVie | Humira | $173 | 10 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $96 | 5 payments
|
| Gilead Sciences | None | $62 | 2 payments
|
| Daiichi Sankyo | Injectafer | $43 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $40 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $27 | 2 payments
|
| Alfasigma USA | None | $26 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $18 | 1 payment
|
2019: $1,060
| Janssen Biotech | Stelara | $211 | 18 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $135 | 8 payments
|
| AbbVie | Humira | $123 | 7 payments
|
| Pfizer | Inflectra | $101 | 5 payments
|
| Janssen Scientific Affairs | Stelara | $100 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $91 | 6 payments
|
| Ucb | Cimzia | $68 | 3 payments
|
| Shionogi | Mulpleta | $41 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $36 | 2 payments
|
| QOL Medical | Sucraid | $33 | 2 payments
|
| Allergan | Zenpep | $26 | 2 payments
|
| Daiichi Sankyo | Injectafer | $21 | 1 payment
|
| Endo Pharmaceuticals | Nascobal | $21 | 1 payment
|
| Gilead Sciences | None | $20 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $18 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $17 | 1 payment
|
Checkups this office reported
16 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 87.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 98%That's most of the people this applied to. | 328 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 45%That's less than half. | 438 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 3%That's few of the people this applied to. Better on this measure. | 89 |
| Breast cancer screeningEligible women who got a mammogram | 80%That's most of the people this applied to. | 501 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 38%That's less than half. | 369 |
| Checked for fall riskOlder patients screened for fall risk | 19%That's few of the people this applied to. | 707 |
| Colon cancer screeningEligible adults who got a colon cancer test | 73%That's more than half. | 784 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 15%That's few of the people this applied to. | 948 |
See the other 8 measures
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 11%That's few of the people this applied to. | 106 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 73%That's more than half. Worse on this measure. | 106 |
| HIV screeningEligible patients who were screened for HIV | 19%That's few of the people this applied to. | 628 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 1,719 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 265 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 100%That's most of the people this applied to. | 720 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 77%That's most of the people this applied to. | 356 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 52%That's more than half. | 1,282 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
Professional record
- NPI
- 1679684245
- Licence
- CA A93605California A93605: Current · expires 2027-03-31
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 2510 Webster St Ste 425, Berkeley, CA, 94705
- NPI first listed
- 2006-08-31
- NPI last updated
- 2024-11-13
- NPI record certified
- 2024-11-13
This is when the NPI record was last certified, not a medical board exam.